MediPrint Ophthalmics announced promising findings from the SIGHT-2 phase 2b study evaluating safety and efficacy of the company’s novel drug-eluting contact lens. The weekly contact lens uses the company’s proprietary 3D printing technology to release a preservative-free formulation of bimatoprost to treat glaucoma.

SIGHT-2 was a 3-week study that included 28 patients diagnosed with open-angle glaucoma randomized to the contact lens vs a control arm assigned to bimatoprost 0.01% ophthalmic solution, according to a news release. Both groups achieved a sustained reduction of about 30% from baseline intraocular pressure. There were no serious treatment-emergent adverse events reported, and the lenses were well tolerated. 

Using the CLDEQ-8 questionnaire, patients in the lens arm reported significant improvements in dry eye and end-of-the-day contact lens comfort, MediPrint stated.